Effective Treatment of Severe Bleeding due to Acquired Thrombocytopathia by Single Dose Administration of Activated Recombinant Factor VII

Please copy the URL and add it into your RSS Feed Reader.

Thromb Haemost 1998; 80(01): 204-205
DOI: 10.1055/s-0037-1615168

Letters to the Editor

Schattauer GmbH

Authors

K. Meijer

¹Division of Thrombosis, Haemostasis and Rheology
E. Sieders

²Department of Surgery, Divisions of Hepatobiliary Surgery and Liver Transplantation
M. J. H. Slooff

²Department of Surgery, Divisions of Hepatobiliary Surgery and Liver Transplantation
J. Th. M. de Wolf

³Department of Hematology, University Hospital Groningen, The Netherlands
J. van der Meer

¹Division of Thrombosis, Haemostasis and Rheology

Received 23 December 1998

Accepted after revision 31 March 1998

Publication Date:
08 December 2017 (online)

References
1 Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa.. Thromb Haemost 1996; 75: 981-2.

Reference Link Ris
Thieme Connect PubMed Search in Google Scholar
2 Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia.. Haemostasis 1996; 26 (Suppl. 01) 159-64.

Reference Link Ris
PubMed Search in Google Scholar
3 Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor.. Br J Haematol 1998; 99: 542-7.

Reference Link Ris
PubMed Search in Google Scholar